
Committee’s Recommendation on BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax Marks a Major Step Toward Closing the Gray Market


Enhanced Positioned to Benefit as the Regulatory Pathway Advances


Enhanced Group Inc.

<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<b xmlns="http://www.w3.org/1999/xhtml">Committee’s Recommendation on BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax Marks a Major Step Toward Closing the Gray Market</b>

</p><p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<b xmlns="http://www.w3.org/1999/xhtml">Enhanced Positioned to Benefit as the Regulatory Pathway Advances</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ENHA">ENHA</a>) the elite sports competition and personalized performance products company commended the United States Food &amp; Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) for its vote last week recommending that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to the FDA&#39;s Section 503A Bulk Drug Substances List. This recommendation is a critical step toward providing licensed U.S. compounding pharmacies a legal, regulated pathway to prepare these peptides for consumers, many of whom currently secure these substances via unregulated providers.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;This is the outcome and regulatory direction the peptide industry has needed, and it provides a path toward smart oversight instead of unregulated ambiguity,&#34; said Maximilian Martin, Co-Founder and CEO of Enhanced. &#34;The Committee chose to engage seriously with the evidence, and we commend the FDA for convening the correct expert testimony and taking this work as seriously as they did. This recommendation is real, meaningful progress toward a regulated market where patients can trust what they&#39;re putting in their bodies from reputable U.S. based compounding sources.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
For years, peptides like BPC-157 and KPV have been sold almost exclusively through unregulated online channels, with no consistent oversight of purity, sterility, or dosing. A pathway through the 503A Bulks List would allow licensed pharmacists to compound these substances under proper supervision replacing anonymous gray-market sourcing with documented, accountable supply chains.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced submitted a formal comment letter to the docket in support of expanding this pathway, co-signed by the Company&#39;s Independent Medical Commission, reflecting its long-standing position that peptide access should run through licensed U.S. 503A and 503B compounding pharmacies rather than unregulated suppliers.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced wishes to provide clarity for its shareholders about exactly where this process stands and how the company is positioned to take full advantage of a regulated marketplace.

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
On July 23-24, 2026, the PCAC voted to recommend BPC-157, KPV, MOTS-c,TB-500, Epitalon and Semax for inclusion on the 503A Bulks List.

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
The PCAC&#39;s vote is a recommendation to the FDA, not a final agency decision. Though the FDA has historically followed PCAC guidance in most cases.

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Formal inclusion on the 503A Bulks List requires the FDA to complete notice-and-comment rulemaking, a process that industry observers estimate could take months following a positive recommendation.

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Enhanced Positioned for Market Expansion</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced has operated exclusively through licensed U.S. 503A and 503B compounding pharmacies since its founding, specifically to keep its supply chain aligned with the standards the FDA is now moving to formalize. Management believes that if the FDA follows the Committee&#39;s recommendation and completes rulemaking, the company’s existing compounding-pharmacy relationships, medical oversight infrastructure, and Live Enhanced telehealth platform will best position the Company to offer newly compoundable peptides to patients through a compliant, prescription-based channel quickly upon approval.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Beyond Single Substances: A Pathway for Personalized Protocols</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Management noted that the Committee&#39;s discussions extended beyond individual substance approvals to how those substances can be layered into personalized, physician-directed protocols. The Company intends to offer a pathway to the following protocols upon regulation:

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Wolverine Stack</b> (BPC-157 + TB-500): pairs localized tissue repair with systemic soft-tissue recovery, with particular relevance for athletic recovery

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">GLOW Stack</b> (BPC-157 + TB-500 + GHK-Cu): builds on the Wolverine combination with a collagen-remodeling copper peptide for skin quality

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">KLOW Stack</b> (BPC-157 + TB-500 + GHK-Cu + KPV): adds a direct anti-inflammatory peptide for comprehensive coverage across healing, skin, and gut health

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Personalization as the Company&#39;s Core Differentiator</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Regulatory clearance for compounding is critical to industry growth; however, the differentiator is precision in how therapies are prescribed and personalized to the individual, particularly in combination. Enhanced&#39;s medical and scientific commissions have built protocol-design expertise validated at the first Enhanced Games. This precision knowledge is what the company intends to make available to its consumers, in personalized protocols that are tailored to the individual based on their specific baseline, as well as their personal goals.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;We built our model around the assumption that longevity and performance medicine regulation was coming,&#34; said Martin. "As the FDA finalizes this pathway, we intend to be ready to bring these therapies to patients at the highest medical and clinical standards similar to our IRB clinical trial we used with our athletes. There is no one-size-fits-all approach to enhancement, the right protocol today for a patient may be different than it was six months ago, and it could be different six months from now. Personalization is what differentiates Enhanced, not just safe access to peptides, but the ability to get the right therapy, at the right dose, at the right time, for the right person.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Enhanced Group, Inc.</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ENHA">ENHA</a>) is an elite sports competition and performance products company committed to giving athletes and people alike access to products and protocols that optimize health, performance, and recovery, through its Enhanced Games, Enhanced Breakers series events and its Live Enhanced consumer telehealth platform.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the anticipated timing, outcome, and effects of FDA rulemaking related to peptide compounding, and Enhanced&#39;s future business opportunities related thereto. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including that: the FDA may decline to follow the PCAC&#39;s recommendation in whole or in part; the rulemaking process may be delayed, modified, or not completed; any final rule may impose conditions that differ from what the Committee recommended; and even if a compounding pathway is finalized, there is no guarantee of consumer demand, competitive positioning, or financial results for Enhanced. Enhanced undertakes no obligation to update these statements except as required by law.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260727193803r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260727193803/en/" rel="nofollow">https://www.businesswire.com/news/home/20260727193803/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:media@enhanced.com" shape="rect">media@enhanced.com</a>

</p>

ENHA

Enhanced Applauds FDA Advisory Committee's Landmark Vote to Expand Legal Compounding Pathway for Peptides

FDA PCAC Recommendation Could Expand ENHA's Regulated Peptide Market

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Committee’s Recommendation on BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax Marks a Major Step Toward Closing the Gray Market


Enhanced Positioned to Benefit as the Regulatory Pathway Advances


Enhanced Group Inc.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>PCAC recommended six peptides for the 503A Bulks List on July 23-24, 2026, with FDA finalization pending. ENHA’s 503A/503B-compliant model and Live Enhanced platform could rapidly serve newly regulated therapies via physician-directed protocols, expanding addressable demand and creating a high-margin, prescription-based revenue stream if rulemaking proceeds.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>PCAC recommended BPC-157, KPV, MOTS-c, TB-500, Epitalon, Semax for 503A.</li><li>ENHA positioned to benefit if FDA advances the pathway.</li><li>Final FDA decision pending; rulemaking could take months.</li><li>Enhanced cites 503A/503B alignment and Live Enhanced platform.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Enhanced Group, Inc. (ENHA)</strong>: Regulatory tailwinds from 503A expansion could unlock new peptide sales channels.</li><li><strong>U.S. Food and Drug Administration (FDA)</strong>: Final rulemaking will determine whether the 503A pathway becomes active; timeline uncertain.</li><li><strong>Pharmacy Compounding Advisory Committee (PCAC)</strong>: Vote supports listing peptides on 503A; non-binding until FDA acts.</li><li><strong>Independent Medical Commission (IMC)</strong>: Co-signed comment; aligns clinical oversight with regulated pathway.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: regulatory advancement could reshape ENHA&#039;s growth trajectory by enabling a licensed, prescription-based peptide market and reducing gray-market exposure.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regulatory tailwind for ENHA&#039;s peptide products could expand addressable market.</li><li>FDA rulemaking timeline may introduce near-term volatility around ENHA.</li><li>ENHA&#039;s 503A/503B model and telehealth platform support rapid commercialization.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>PCAC vote occurred July 23-24, 2026.</li><li>Six peptides considered: BPC-157, KPV, MOTS-c, TB-500, Epitalon, Semax.</li><li>FDA final rulemaking required; timeline could be months.</li><li>ENHA operates exclusively through U.S. 503A and 503B pharmacies.</li><li>Enhanced co-signed a comment letter with Independent Medical Commission.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish in 6–12 months if FDA finalizes the 503A pathway; watch for rulemaking progress.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<b xmlns="http://www.w3.org/1999/xhtml">Committee’s Recommendation on BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax Marks a Major Step Toward Closing the Gray Market</b>

</p><p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<b xmlns="http://www.w3.org/1999/xhtml">Enhanced Positioned to Benefit as the Regulatory Pathway Advances</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ENHA">ENHA</a>) the elite sports competition and personalized performance products company commended the United States Food &amp; Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) for its vote last week recommending that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to the FDA&#39;s Section 503A Bulk Drug Substances List. This recommendation is a critical step toward providing licensed U.S. compounding pharmacies a legal, regulated pathway to prepare these peptides for consumers, many of whom currently secure these substances via unregulated providers.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;This is the outcome and regulatory direction the peptide industry has needed, and it provides a path toward smart oversight instead of unregulated ambiguity,&#34; said Maximilian Martin, Co-Founder and CEO of Enhanced. &#34;The Committee chose to engage seriously with the evidence, and we commend the FDA for convening the correct expert testimony and taking this work as seriously as they did. This recommendation is real, meaningful progress toward a regulated market where patients can trust what they&#39;re putting in their bodies from reputable U.S. based compounding sources.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
For years, peptides like BPC-157 and KPV have been sold almost exclusively through unregulated online channels, with no consistent oversight of purity, sterility, or dosing. A pathway through the 503A Bulks List would allow licensed pharmacists to compound these substances under proper supervision replacing anonymous gray-market sourcing with documented, accountable supply chains.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced submitted a formal comment letter to the docket in support of expanding this pathway, co-signed by the Company&#39;s Independent Medical Commission, reflecting its long-standing position that peptide access should run through licensed U.S. 503A and 503B compounding pharmacies rather than unregulated suppliers.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced wishes to provide clarity for its shareholders about exactly where this process stands and how the company is positioned to take full advantage of a regulated marketplace.

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
On July 23-24, 2026, the PCAC voted to recommend BPC-157, KPV, MOTS-c,TB-500, Epitalon and Semax for inclusion on the 503A Bulks List.

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
The PCAC&#39;s vote is a recommendation to the FDA, not a final agency decision. Though the FDA has historically followed PCAC guidance in most cases.

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Formal inclusion on the 503A Bulks List requires the FDA to complete notice-and-comment rulemaking, a process that industry observers estimate could take months following a positive recommendation.

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Enhanced Positioned for Market Expansion</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced has operated exclusively through licensed U.S. 503A and 503B compounding pharmacies since its founding, specifically to keep its supply chain aligned with the standards the FDA is now moving to formalize. Management believes that if the FDA follows the Committee&#39;s recommendation and completes rulemaking, the company’s existing compounding-pharmacy relationships, medical oversight infrastructure, and Live Enhanced telehealth platform will best position the Company to offer newly compoundable peptides to patients through a compliant, prescription-based channel quickly upon approval.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Beyond Single Substances: A Pathway for Personalized Protocols</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Management noted that the Committee&#39;s discussions extended beyond individual substance approvals to how those substances can be layered into personalized, physician-directed protocols. The Company intends to offer a pathway to the following protocols upon regulation:

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Wolverine Stack</b> (BPC-157 + TB-500): pairs localized tissue repair with systemic soft-tissue recovery, with particular relevance for athletic recovery

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">GLOW Stack</b> (BPC-157 + TB-500 + GHK-Cu): builds on the Wolverine combination with a collagen-remodeling copper peptide for skin quality

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">KLOW Stack</b> (BPC-157 + TB-500 + GHK-Cu + KPV): adds a direct anti-inflammatory peptide for comprehensive coverage across healing, skin, and gut health

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Personalization as the Company&#39;s Core Differentiator</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Regulatory clearance for compounding is critical to industry growth; however, the differentiator is precision in how therapies are prescribed and personalized to the individual, particularly in combination. Enhanced&#39;s medical and scientific commissions have built protocol-design expertise validated at the first Enhanced Games. This precision knowledge is what the company intends to make available to its consumers, in personalized protocols that are tailored to the individual based on their specific baseline, as well as their personal goals.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;We built our model around the assumption that longevity and performance medicine regulation was coming,&#34; said Martin. "As the FDA finalizes this pathway, we intend to be ready to bring these therapies to patients at the highest medical and clinical standards similar to our IRB clinical trial we used with our athletes. There is no one-size-fits-all approach to enhancement, the right protocol today for a patient may be different than it was six months ago, and it could be different six months from now. Personalization is what differentiates Enhanced, not just safe access to peptides, but the ability to get the right therapy, at the right dose, at the right time, for the right person.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Enhanced Group, Inc.</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Enhanced (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ENHA">ENHA</a>) is an elite sports competition and performance products company committed to giving athletes and people alike access to products and protocols that optimize health, performance, and recovery, through its Enhanced Games, Enhanced Breakers series events and its Live Enhanced consumer telehealth platform.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the anticipated timing, outcome, and effects of FDA rulemaking related to peptide compounding, and Enhanced&#39;s future business opportunities related thereto. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including that: the FDA may decline to follow the PCAC&#39;s recommendation in whole or in part; the rulemaking process may be delayed, modified, or not completed; any final rule may impose conditions that differ from what the Committee recommended; and even if a compounding pathway is finalized, there is no guarantee of consumer demand, competitive positioning, or financial results for Enhanced. Enhanced undertakes no obligation to update these statements except as required by law.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260727193803r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260727193803/en/" rel="nofollow">https://www.businesswire.com/news/home/20260727193803/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:media@enhanced.com" shape="rect">media@enhanced.com</a>

</p>

PCAC recommended six peptides for the 503A Bulks List on July 23-24, 2026, with FDA finalization pending. ENHA’s 503A/503B-compliant model and Live Enhanced platform could rapidly serve newly regulated therapies via physician-directed protocols, expanding addressable demand and creating a high-margin, prescription-based revenue stream if rulemaking proceeds.

News insight

Enhanced Applauds FDA Advisory Committee's Landmark Vote to Expand Legal Compounding Pathway for Peptides

AI summary

Sentiment rationale

Key facts

Industry News